

22nd Congress of the EAHP Cannes 2017 March 22-24

### CP-155



# PREVALENCE AND EFFECTIVINESS OF ANTIRETROVIRAL TREATMENT COMBINATIONS USED IN HIV PATIENTS NOT COLLECTED IN GUIDELINES

L.Ruiz González<sup>1</sup>, A. Álvarez Nonay<sup>1</sup>, M. Torralba González de Suso<sup>2</sup>, M. Rodríguez Zapata<sup>2</sup>, A. Horta Hernández<sup>1</sup>, A. Lázaro López<sup>1</sup>.

1. Guadalajara University Hospital, Pharmacy Department, Guadalajara, Spain.

2. Guadalajara University Hospital, Internal medicine, Guadalajara, Spain

## BACKGROUNE

Most studies in HIV-infected patients focus on effectiveness of antiretroviral therapies (ART) combinations included in clinical Guidelines. However few studies analyze the combinations not listed in these Guidelines

## **OBJECTIVES**

METHODS

RESULTS

To analyze the prevalence and effectiveness of ART combinations not included in HIV Guidelines

A retrospective observational study was carried out between January 2014 and December 2015. All patients with ART followed for at least 1 year by the Outpatient Pharmacy were included.

### ART were classified in two groups:

All combinations listed in the Spanish National AIDS Plan Recommended Guidelines (GESIDA) for initial antiretroviral therapy 2014-2015.

Combinations not listed in GESIDA Guidelines.

To determine the effectiveness of the treatment, plasma viral load (VL) and CD4 + lymphocytes were reviewed. Two analyses according to different criteria were conducted:

Criteria reflected in Spanish GESIDA Guidelines: VL<50 copies/ml (undetectable) and CD4 repeatedly greater</p>


than 300 cells/µL, at least twice consecutive.

Criteria reflected in American DHHS Guidelines: VL<200 copies/ml (to prevent errors by blip) and CD4 repeatedly greater than 300 cells/µL, at least twice consecutive.</p>

Data were analysed with SPSS 20.0 software.

245 patients were analyzed. 68,6% (168) were male. The median age was 48,5 years (IIC: 43,5 to 53).

Patients	ART combinations included in guidelines	ART combinations not included in guidelines		ETR + DRV/r DRV/r + DOL ó RAL
Total (n,%)	224 (91,4%)	21 (8,6%)		DRV/r + RAL ó DOL + MVC
VL <50 copies/ml and CD4>300 cells/µL	110 (49,1%)	9 (42,9%)	OR = 1.287; 95% CI OR: 0521-3174;	TDF ó ABC +DRV/r + RAL 3TC + ETR + DRV/r + RAL



Y This study shows that few patients receive ART combinations not collected in clinical practice Guidelines.

The high power of current ART could explain the similar effectiveness between listed and not listed therapies in the Guidelines.

#### **NO CONFLICT OF INTEREST**